Other Consolidated Financial Statement Detail

Supplemental Cash Flow Information

Supplemental disclosure of cash flow information for the years ended December 31, 2013, 2012 and 2011, is as follows:



	For the Years Ended December 31,
(In millions)	2013		2012		2011
Cash paid during the year for:
Interest	$	53.6	$	65.4	$	66.7
Income taxes	$	643.2	$	526.6	$	332.7

Non-cash Investing and Financing Activity

In July and November 2013, the construction of the two office buildings was completed and we started leasing the facilities. Upon completion of the construction of the buildings, we determined that we were no longer considered the owner of the buildings because we do not have any unusual or significant continuing involvement. Consequently, we derecognized the buildings and their associated financing obligation of approximately $161.5 million from our consolidated balance sheet. For additional information related to these transactions, please read Note 11, Property, Plant & Equipment to these consolidated financial statements.

In March 2012, upon completion of our acquisition of Stromedix, we recorded $219.2 million of in-process research and development and $48.2 million of goodwill. In addition, we also recorded a contingent consideration obligation of $122.2 million.

In September 2011, upon completion of our acquisition of the noncontrolling interest in our joint venture investments in Biogen Dompé SRL and Biogen Dompé Switzerland GmbH, we recorded a contingent consideration obligation of $38.8 million.

Other Income (Expense), Net

Components of other income (expense), net, are summarized as follows:



	For the Years Ended December 31,
(In millions)	2013			2012			2011
Interest income	$	8.2		$	29.5		$	19.2
Interest expense	(31.9		)	(36.5		)	(33.0		)
Impairments on investments	(2.8		)	(5.5		)	(9.9		)
Gain (loss) on investments, net	21.7			10.6			18.8
Foreign exchange gains (losses), net	(15.2		)	(2.5		)	(6.3		)
Other, net	(14.9		)	3.7			(2.3		)
Total other income (expense), net	$	(34.9	)	$	(0.7	)	$	(13.5	)

For 2013 compared to 2012, the change in other income (expense), net was due to a decrease in interest income due to lower average cash, cash equivalent and marketable securities balances primarily related to the use of cash in connection with our acquisition of TYSABRI rights from Elan and the repayment of our 6.0% Senior Notes, a decrease in other, net primarily related to higher non-income based state taxes and higher foreign exchange losses.

Accrued Expenses and Other

Accrued expenses and other consists of the following:



	As of December 31,
(In millions)	2013		2012
Employee compensation and benefits	$	343.4	$	248.5
Revenue-related rebates	264.9		191.0
Deferred revenue	172.7		148.0
Royalties and licensing fees	160.7		45.2
Clinical development expenses	55.2		51.6
Current portion of contingent consideration obligations	29.0		22.4
Construction in progress accrual	25.0		12.3
Collaboration expenses	18.7		37.4
Other	285.6		223.5
Total accrued expenses and other	$	1,355.2	$	979.9